Sign in
Taking people in United StatesNo phase

Tests Myfortic to prevent immune sensitization after islet transplant loss in type 1 diabetes

Tests Myfortic in adults with type 1 diabetes whose islet transplant was lost.

Key facts

Who runs it
Rodolfo Alejandro
Where
Miami, United StatesSee the site
Trial code
Registry title
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
Status
Recruiting
People taking part
18 people, planned
Started
Jan 2009
Expected to end
Dec 2028
Type of study
Interventional
Treatments tested
  • Myfortic
Record updated
23 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who had at least one islet transplant and have now completely lost the graft. They take Myfortic alone to try to prevent new sensitization (new antibodies against donor tissue).

Age
18 to 70 years
Sex
Men and women
Disease stage
Complete islet graft loss or rejection, with stimulated C-peptide below 0.3 ng/ml.
Earlier treatment
At least one islet transplant. Currently taking immunosuppressive medicines, or stopping them as set by the islet transplant protocol.
Biomarker or test result
Stimulated C-peptide below 0.3 ng/ml.

Main reasons for not taking part

  • Positive pregnancy test or breast-feeding
  • Active infection, including hepatitis B, hepatitis C, HIV or TB
  • Any past cancer, except fully removed squamous or basal skin cancer
  • PRA of 50% or more, or significant sensitization judged by the investigator
  • Active alcohol or substance abuse

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Male and female patients age 18-70 years of age
  • Ability to provide written informed consent
  • Mentally stable and able to comply with the procedures of the study protocol
  • Any subject currently prescribed immunosuppressive medications or discontinuation of immunosuppressive medications indicated as per current protocol of islet transplantation
  • History of at least one islet transplant
  • Stimulated C-peptide <0.3 ng/ml

Who cannot take part

  • Known history of untreated severe hyperlipidemia, obesity, or refractory hypertension
  • History of active infection including hepatitis B, hepatitis C, HIV, or TB
  • Any history of malignancy except for completely resected squamous or basal skin cell carcinoma
  • Evidence of inter-current infection
  • Active peptic ulcer disease
  • Severe co-existing history of cardiac disease, characterized by a history of any one of these conditions: recent myocardial infarction (within past 6 months), evidence of ischemia on functional cardiac exam within the last year, or left ventricular ejection fraction <30%
  • History of persistent elevation of liver function tests. SGOT (AST), SGPT (ALT), alkaline phosphatase or total bilirubin, with values >1.5 times normal upper limits will exclude a patient
  • For female participants: Positive pregnancy test or presently breast-feeding
  • Known active alcohol or substance abuse
  • History on non-adherence to prescribed regimens including immunosuppression
  • PRA ≥ 50% or evidence of significant sensitization to be determined at discretion of the investigator

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

  • Diabetes Research InstituteMiami, United StatesContact: Rodolfo Alejandro, MDTaking people

About the trial

What the trial wants to find out

This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.

The group in the trial

  • Myfortic treatmentTreatment being tested

    Treatment with Myfortic

    Treatment: Myfortic

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Myfortic® Monotherapy to Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
Plain-language title
Tests Myfortic to prevent immune sensitization after islet transplant loss in type 1 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT01999361, who can take part
Publications
Record updated
23 March 2026